依达拉奉在急性期脑梗死患者中的有效性及安全性分析  

Analysis of Effectiveness and Safety of Edaravone in Patients With Acute Cerebral Infarction

作　　者：田亮[1] 鄢圣娟 TIAN Liang;YAN Shengjuan(Department of Neurology,Qianjiang Central Hospital,Qianjiang Hubei 433100,China)

机构地区：[1]湖北省潜江市中心医院神经科,湖北潜江433100

出　　处：《中国继续医学教育》2018年第11期118-119,共2页China Continuing Medical Education

摘　　要：目的分析研讨依达拉奉在急性期脑梗死患者中的有效性及安全性。方法选取2015年4月—2017年4月收治的急性期脑梗死患者80例,用1∶1随机数字法分两组讨论。对照组接受川芎嗪注射液+阿司匹林+胞二磷胆碱注射液治疗,研究组在对照组治疗基础上接受依达拉奉治疗,观察两组患者治疗状况。结果对比两组患者NIHSS、Barthel评分,治疗前P>0.05;治疗后,研究组NIHSS评分低于对照组,Barthel评分高于对照组,且P<0.05。结论依达拉奉治疗急性期脑梗死疗效突出,患者神经功能和生活质量均可得到更为明显的改善。Objective To analyze and discuss the effectiveness and safety of edaravone in patients with acute cerebral infarction.Methods 80 cases of patients with acute cerebral infarction and who treated from April 2015 to April 2017 were divided into two groups into the discussion by the 1:1 random numeric method.The control group were given ligustrazine Injection+aspirin+citicoline Injection,while the study group were treated with edaravone on the basis of treatment in the control group.Then,the treatment status of two groups of patients were observed.Results The NIHSS and Barthel scores of two groups were compared and before treatment P>0.05.After the treatment,the NIHSS score in the study group was lower than that in the control group,and the Barthel score was higher than that in the control group,and P<0.05.Conclusion The clinical effect of edaravone in treatment of acute cerebral infarction are prominent,which it can be improved more clearly the patient's nerve function and quality of life.

关 键 词：脑梗死 依达拉奉 急性 

分 类 号：R743[医药卫生—神经病学与精神病学]